Hims names Dr. Anant Vinjamoori as Chief Medical Officer
Vinjamoori brings expertise in longevity medicine to lead clinical guidance across multiple health categories.
See the latest news and media coverage for Hims. We track all announcements, press releases, and industry mentions in real time, all in one place.
Men's health telehealth provider
hims.comLast updated
In short: Hims expanded its global footprint and weight-loss portfolio, despite facing legal challenges, a data breach, and intense market competition.
Vinjamoori brings expertise in longevity medicine to lead clinical guidance across multiple health categories.
It now has a leading presence across the US, UK, Australia, Canada, and Japan, aiming for $6.5B revenue by 2030.
The medication offers affordable GLP-1 treatment for weight management and type 2 diabetes, with personalized care plans starting at $149/mo CAD.
The $300M offering aims to fund international expansion, including the Eucalyptus acquisition, and AI investments.
Shares of Hims & Hers Health (HIMS) slipped 2% in overnight trading late Sunday after the company's chief medical officer filed to sell shares, while...
Hims & Hers management targets at least $6.5B in revenue and $1.3B in adjusted EBITDA by 2030 through platform expansion. Read more on HIMS stock...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or...
Lupton projects the global peptide market could generate $250 billion to $380 billion in annual...
Track Hims and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to Hims and other trending companies.